Peters MF - Search Results

1

Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1.

Brugel TA, Smith RW, Balestra M, Becker C, Daniels T, Hoerter TN, Koether GM, Throner SR, Panko LM, Folmer JJ, Cacciola J, Hunter AM, Liu R, Edwards PD, Brown DG, Gordon J, Ledonne NC, Pietras M, Schroeder P, Sygowski LA, Hirata LT, Zacco A, Peters MF. Brugel TA, et al. Among authors: peters mf. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5847-52. doi: 10.1016/j.bmcl.2010.07.113. Epub 2010 Jul 30. Bioorg Med Chem Lett. 2010. PMID: 20727752

2

Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity.

Peters MF, Zacco A, Gordon J, Maciag CM, Litwin LC, Thompson C, Schroeder P, Sygowski LA, Piser TM, Brugel TA. Peters MF, et al. Eur J Pharmacol. 2011 Jul 1;661(1-3):27-34. doi: 10.1016/j.ejphar.2011.04.017. Epub 2011 Apr 27. Eur J Pharmacol. 2011. PMID: 21539838

3

SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2.

Brugel TA, Smith RW, Balestra M, Becker C, Daniels T, Koether GM, Throner SR, Panko LM, Brown DG, Liu R, Gordon J, Peters MF. Brugel TA, et al. Among authors: peters mf. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10. doi: 10.1016/j.bmcl.2010.07.112. Epub 2010 Aug 3. Bioorg Med Chem Lett. 2010. PMID: 20719509

4

Evaluation of cellular dielectric spectroscopy, a whole-cell, label-free technology for drug discovery on Gi-coupled GPCRs.

Peters MF, Knappenberger KS, Wilkins D, Sygowski LA, Lazor LA, Liu J, Scott CW. Peters MF, et al. J Biomol Screen. 2007 Apr;12(3):312-9. doi: 10.1177/1087057106298637. Epub 2007 Feb 16. J Biomol Screen. 2007. PMID: 17307886

5

Human induced pluripotent stem cells and their use in drug discovery for toxicity testing.

Scott CW, Peters MF, Dragan YP. Scott CW, et al. Among authors: peters mf. Toxicol Lett. 2013 May 10;219(1):49-58. doi: 10.1016/j.toxlet.2013.02.020. Epub 2013 Mar 5. Toxicol Lett. 2013. PMID: 23470867 Review.

6

Comparing label-free biosensors for pharmacological screening with cell-based functional assays.

Peters MF, Vaillancourt F, Heroux M, Valiquette M, Scott CW. Peters MF, et al. Assay Drug Dev Technol. 2010 Apr;8(2):219-27. doi: 10.1089/adt.2009.0232. Assay Drug Dev Technol. 2010. PMID: 20085460

7

Cardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches.

Lamore SD, Kohnken RA, Peters MF, Kolaja KL. Lamore SD, et al. Among authors: peters mf. Chem Res Toxicol. 2020 Jan 21;33(1):125-136. doi: 10.1021/acs.chemrestox.9b00387. Epub 2020 Jan 10. Chem Res Toxicol. 2020. PMID: 31840498 Review.

8

Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity.

Lamore SD, Kamendi HW, Scott CW, Dragan YP, Peters MF. Lamore SD, et al. Among authors: peters mf. Toxicol Sci. 2013 Oct;135(2):402-13. doi: 10.1093/toxsci/kft167. Epub 2013 Jul 28. Toxicol Sci. 2013. PMID: 23897988

9

Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications.

Peters MF, Scott CW, Ochalski R, Dragan YP. Peters MF, et al. Assay Drug Dev Technol. 2012 Dec;10(6):525-32. doi: 10.1089/adt.2011.442. Epub 2012 May 10. Assay Drug Dev Technol. 2012. PMID: 22574652

10

An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility.

Scott CW, Zhang X, Abi-Gerges N, Lamore SD, Abassi YA, Peters MF. Scott CW, et al. Among authors: peters mf. Toxicol Sci. 2014 Dec;142(2):331-8. doi: 10.1093/toxsci/kfu186. Epub 2014 Sep 18. Toxicol Sci. 2014. PMID: 25237062

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters